| Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study. (NCT05282082) | Erasmus Medical Center | 2022-03-01 |
| Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis (NCT04596319) | Armata Pharmaceuticals, Inc. | 2020-12-22 |
| Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies (NCT04335383) | University Hospital, Grenoble | 2020-10-05 |
| Cross Transmissions of Pseudomonas Aeruginosa Between Children From a Same Cystic Fibrosis Center. (NCT03910920) | Queen Fabiola Children's University Hospital | 2019-02-06 |
| Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease (NCT04803695) | Hospital Clinic of Barcelona | 2018-03-01 |
| Targeted AntiBiotics for Chronic Pulmonary Diseases (NCT03262142) | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | 2018-01-10 |
| Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections (NCT03510351) | Temple University | 2017-02-01 |
| Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects (NCT02696902) | MedImmune LLC | 2016-03-25 |
| Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN) (NCT01745796) | University Hospital, Grenoble | 2013-07-03 |
| The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis (NCT01616862) | Zafer Soultan | 2012-02-01 |
| Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways (NCT01404234) | Gilead Sciences | 2011-12-01 |
| A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies (NCT01319253) | Indiana University | 2011-03-01 |
| Second Open Label Extension to Bridging Study CTBM100C2303 (NCT01069705) | Novartis Pharmaceuticals | 2010-02-12 |
| Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization (NCT01035853) | University of Jena | 2009-12-01 |
| Open Label Extension to Bridging Study CTBM100C2303 (NCT00982930) | Novartis Pharmaceuticals | 2009-08-12 |
| Volatile Organic Compounds in Cystic Fibrosis (NCT01379040) | Landon Pediatric Foundation | 2009-08-01 |
| Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization (NCT00774072) | University of Jena | 2008-10-01 |
| Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (NCT00712166) | Gilead Sciences | 2008-05-01 |
| Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa (NCT00691587) | Humanigen, Inc. | 2008-04-01 |
| Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo (NCT00515229) | University Hospital Tuebingen | 2006-10-01 |
| Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis (NCT00633191) | Immunsystem AB | 2003-11-01 |
| Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection (NCT01055847) | Gilead Sciences | 2003-06-01 |
| Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis (NCT00333385) | Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche | 2001-10-01 |
| Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis (NCT00989807) | Gilead Sciences | |